Cochrane · systematic review · CD015102
Prophylactic anticoagulants for non‐hospitalised people with COVID‐19
Santos, BC, Flumignan, RLG, Civile, VT, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
17
No studies
4
Included studies
NR
No studies 4 · 19%Ungraded 0 · 0%Very low 0 · 0%Low 8 · 38.1%Moderate 9 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Anticoagulant compared to placebo or no treatment for non‐hospitalised people with COVID‐19
Population: non‐hospitalised people with COVID‐19
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Anticoagulant vs placebo or no treatment | RR 0.36 [0.04, 3.61] | 5 studies · 1777 participants | Low Downgraded: risk of bias, imprecision |
Venous thromboembolism Anticoagulant vs placebo or no treatment | RR 0.36 [0.16, 0.85] | 4 studies · 1259 participants | Moderate Downgraded: risk of bias, imprecision |
Major bleeding Anticoagulant vs placebo or no treatment | RR 0.36 [0.01, 8.78] | 5 studies · 1777 participants | Low Downgraded: risk of bias, imprecision |
Deep vein thrombosis Anticoagulant vs placebo or no treatment | RR 1.02 [0.3, 3.46] | 3 studies · 1009 participants | Moderate Downgraded: risk of bias, imprecision |
Pulmonary embolism Anticoagulant vs placebo or no treatment | RR 0.25 [0.08, 0.79] | 3 studies · 1009 participants | Moderate Downgraded: risk of bias, imprecision |
Need for hospitalisation Anticoagulant vs placebo or no treatment | RR 1.01 [0.59, 1.75] | 4 studies · 1459 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse events (minor bleeding) Anticoagulant vs placebo or no treatment | RR 2.46 [0.9, 6.72] | 5 studies · 1777 participants | Low Downgraded: risk of bias, imprecision |
Anticoagulant compared to different dose of the same anticoagulant for non‐hospitalised people with COVID‐19
Population: non‐hospitalised people with COVID‐19
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Anticoagulant vs different dose of the same anticoagulant | no estimate extracted | 1 study · 278 participants | Moderate Downgraded: imprecision |
Venous thromboembolism Anticoagulant vs different dose of the same anticoagulant | no estimate extracted | 1 study · 278 participants | Moderate Downgraded: imprecision |
Major bleeding Anticoagulant vs different dose of the same anticoagulant | no estimate extracted | 1 study · 278 participants | Moderate Downgraded: imprecision |
Deep vein thrombosis Anticoagulant vs different dose of the same anticoagulant | no estimate extracted | NR | No studies |
Pulmonary embolism Anticoagulant vs different dose of the same anticoagulant | no estimate extracted | NR | No studies |
Need for hospitalisation Anticoagulant vs different dose of the same anticoagulant | RR 1.89 [0.17, 20.58] | 1 study · 278 participants | Low Downgraded: imprecision |
Adverse events (minor bleeding) Anticoagulant vs different dose of the same anticoagulant | RR 0.47 [0.09, 2.54] | 1 study · 278 participants | Low Downgraded: imprecision |
Anticoagulant compared to antiplatelet agent for non‐hospitalised people with COVID‐19
Population: non‐hospitalised people with COVID‐19
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Anticoagulant vs antiplatelet agent | no estimate extracted | 1 study · 279 participants | Moderate Downgraded: imprecision |
Venous thromboembolism Anticoagulant vs antiplatelet agent | RR 0.36 [0.01, 8.65] | 1 study · 279 participants | Low Downgraded: imprecision |
Major bleeding Anticoagulant vs antiplatelet agent | no estimate extracted | 1 study · 279 participants | Moderate Downgraded: imprecision |
Deep vein thrombosis Anticoagulant vs antiplatelet agent | no estimate extracted | NR | No studies |
Pulmonary embolism Anticoagulant vs antiplatelet agent | no estimate extracted | NR | No studies |
Need for hospitalisation Anticoagulant vs antiplatelet agent | RR 3.2 [0.13, 77.85] | 1 study · 279 participants | Low Downgraded: imprecision |
Adverse events (minor bleeding) Anticoagulant vs antiplatelet agent | RR 2.13 [0.4, 11.46] | 1 study · 279 participants | Low Downgraded: imprecision |